Vaccination

Schedule Your COVID-19 Vaccine at Golden Valley Memorial Healthcare

Infectious diseases, Hospitals, Pharmaceutical, Health, Medical research, Vaccination, Vaccine, Virology, COVID-19 vaccine, Medical specialties, Medicine, Health sciences, Ministry of Health
Friday, February 26, 2021 - 1:00pm

Golden Valley Memorial Healthcare (GVMH) is currently scheduling COVID-19 vaccine appointments at its Clinton, Osceola, Warsaw and Windsor facilities.

Key Points: 
  • Golden Valley Memorial Healthcare (GVMH) is currently scheduling COVID-19 vaccine appointments at its Clinton, Osceola, Warsaw and Windsor facilities.
  • To schedule an appointment for the COVID-19 vaccine, please call 660.324.2995.
  • This number is the only way to schedule a vaccine at GVMH.
  • Golden Valley Memorial Healthcare (GVMH) is a leading rural healthcare organization dedicated to providing compassionate, friendly, quality care for patients close to home.

European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older

Health, FDA, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Vaccines, Health care, Medical specialties, Health, Pneumonia, Pneumococcal conjugate vaccine, Vaccination, Pfizer, Vaccine, Conjugate vaccine, Pneumococcal vaccine, Ruth Link-Gelles
Friday, February 26, 2021 - 11:45am

The epidemiology of pneumococcal serotypes causing disease has been changing due to the success of pneumococcal conjugate vaccines targeting pediatric and adult populations.

Key Points: 
  • The epidemiology of pneumococcal serotypes causing disease has been changing due to the success of pneumococcal conjugate vaccines targeting pediatric and adult populations.
  • In June 2020 Pfizer announced initiation of two Phase three trials for 20vPnC evaluating the safety and efficacy of the investigational vaccine in infants.
  • Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
  • Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.

Statement of the members of the European Council on COVID-19 and health, 25 February 2021

Articles, Biotechnology, Vaccination, Pandemic, Vaccine, World Health Organization's response to the COVID-19 pandemic, Vaccination policy
Friday, February 26, 2021 - 8:01am

We are determined to continue to work together and coordinate our action to tackle the pandemic and its consequences.

Key Points: 
  • We are determined to continue to work together and coordinate our action to tackle the pandemic and its consequences.
  • We must therefore uphold tight restrictions while stepping up efforts to accelerate the provision of vaccines.
  • The unhindered flow of goods and services within the Single Market must be ensured, including by making use of Green Lanes.
  • Even so, we need to urgently accelerate the authorisation, production and distribution of vaccines, as well as vaccination.
  • We call for work to continue on a common approach to vaccination certificates and will come back to this issue.
  • We reaffirm our solidarity with third countries and underline our determination to step up our global response to the pandemic.
  • We will continue to keep the overall situation under close review and take action as needed.

II. HEALTH

    • Although the COVID-19 crisis is not yet over, it is time to start strengthening our future health resilience now.
    • We will work to improve EU coordination, in line with the Union competences under the Treaties, to ensure better prevention, preparedness for and response to future health emergencies.
    • Work on the Health Union proposals and on the Pharmaceutical Strategy, including as regards access to medicines across Member States, should also be taken forward.
    • We are committed to advancing global health security, including by strengthening the World Health Organization and working towards an international treaty on pandemics within its framework.
    • In this context, we look forward to the G20 Global Health Summit in Rome.

Remarks by President Charles Michel following the first session of the video conference of the members of the European Council

Biotechnology, Vaccination, Vaccine
Friday, February 26, 2021 - 8:00am

We also discussed the lessons learned from this crisis to strengthen our health systems and improve our EU coordination.

Key Points: 
  • We also discussed the lessons learned from this crisis to strengthen our health systems and improve our EU coordination.
  • VaccinationsOur top priority now is speeding up the production and delivery of vaccines, and vaccinations, across the EU.
  • Thats why we support the Commissions efforts to work with industry to identify bottlenecks, guarantee supply chains, and scale up production.
  • And we want more predictability and transparency to ensure that pharmaceutical companies comply with their commitments.
  • Thats why enhancing our sequencing capacity is key to these efforts.And we need to continue to invest in vaccine research to update our vaccines.
  • More work needs to be done - on digitalisation and on cooperation with the World Health Organisation.
  • But tonight we felt more and more convergence among us on this important topic.The European Council will revert to this matter.
  • Our help should go to all those in need, including in Africa, Western Balkans, Eastern Partnership and Latin America.
  • Je voudrais adresser maintenant quelques commentaires sur la situation dans laquelle nous nous trouvons sur le terrain de la lutte contre le COVID-19.
  • Finally one word on Russia: we will have a strategic debate in March on our relationship with Russia.

Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate

Virology, Medical specialties, Vaccination, Vaccine, Medicine, Clinical medicine, Vaccines, Medical research
Friday, February 26, 2021 - 12:42am

Eurocine Vaccines AB ("Eurocine Vaccines") confirms good immunological effect in a preclinical animal study with its chlamydia vaccine candidate.

Key Points: 
  • Eurocine Vaccines AB ("Eurocine Vaccines") confirms good immunological effect in a preclinical animal study with its chlamydia vaccine candidate.
  • The good immunological effect of the tested vaccine surpasses, by a good margin, what in previous studies with our vaccine has provided protection in preclinical models.
  • STOCKHOLM, Sweden, Feb. 25, 2021 /PRNewswire/ -- In the current study, a chlamydia vaccine candidate, adapted to meet regulatory requirements, has been evaluated.
  • The study shows that Eurocine Vaccines' chlamydia vaccine candidate, after adaptation, remains highly immunogenic and focuses the immune response to the relevant parts of the chlamydia bacterium.

Pioneer Physicians Network Doctors Join Nationwide Physician Campaign Urging Patients to Get COVID-19 Vaccinations

Vaccination, Medical specialties, Epidemiology, Vaccine, Virology, Herd immunity, Health sciences, Health
Thursday, February 25, 2021 - 9:43pm

Already, COVID-19 has taken the lives of over 500,000 Americans and over two million worldwide.

Key Points: 
  • Already, COVID-19 has taken the lives of over 500,000 Americans and over two million worldwide.
  • "We were happy to participate in a national video involving physicians from all over the U.S. urging Americans to get the vaccine -- which will ultimately create herd immunity and stop the spread," says Gary Pinta, M.D., President of Pioneer Physicians Network.
  • "Some of our patients are wary about getting vaccinated and we let them know they have nothing to lose and everything to gain."
  • The campaign is a combined effort between agilon health and primary care physicians representing more than 50 independent physician practices across the country.

Doctors Nationwide Band Together to Launch Initiative Urging Patients to Get Vaccinated for COVID-19

Medical specialties, Vaccination, Medicine, Health sciences, Epidemiology, Immunology, Herd immunity, Prevention, Zoonoses, Vaccine, Cowpox, Immunity
Thursday, February 25, 2021 - 9:40pm

Already, COVID-19 has taken the lives of 500,000 Americans and over two million people worldwide.

Key Points: 
  • Already, COVID-19 has taken the lives of 500,000 Americans and over two million people worldwide.
  • "While we encourage all patients to get vaccinated, we feel compelled to do something on a larger scale to urge patients to create herd immunity, which ultimately will stop the infection and help save lives."
  • 'Herd immunity,' or 'population immunity,' happens when a population is immune either through vaccination or immunity developed through the previous infection.
  • According to research released by the Kaiser Family Foundation , 35 percent of black Americans have expressed hesitancy towards getting vaccinated.

Translate Bio Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Progress

Branches of biology, Biology, Life sciences, RNA, Gene expression, Vaccination, Vaccine, Virology, Cash and cash equivalents, Messenger RNA
Thursday, February 25, 2021 - 9:05pm

2020 ushered in a new era of mRNA possibilitiesfor vaccines and therapeuticsin which the promise of mRNA medicines became a reality, said Ronald Renaud, chief executive officer of Translate Bio.

Key Points: 
  • 2020 ushered in a new era of mRNA possibilitiesfor vaccines and therapeuticsin which the promise of mRNA medicines became a reality, said Ronald Renaud, chief executive officer of Translate Bio.
  • Translate Bio ended the fourth quarter of 2020 with $654.0 million in cash, cash equivalents and investments and 75,029,625 shares of common stock outstanding.
  • General and administrative expenses of $10.7 million during the fourth quarter of 2020, compared to $7.3 million for the same period in 2019.
  • Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver.

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Medical specialties, Vaccines, Vaccination, Vaccine, Virology, Medicine, Health care, Medical research, Hypothetical technology
Thursday, February 25, 2021 - 9:01pm

Vaxart made this announcement as it provided financial results for the fourth quarter and full year endedDecember 31, 2020 and provided a corporate update.

Key Points: 
  • Vaxart made this announcement as it provided financial results for the fourth quarter and full year endedDecember 31, 2020 and provided a corporate update.
  • Vaxart is also advancing S-only vaccine candidates targeted specifically against variant strains, including one targeting the South African viral strain.
  • General and administrative expenses were $5.1 million for the fourth quarter of 2020 compared to $1.3 million for the fourth quarter of 2019.
  • There were no restructuring expenses for the fourth quarter of 2020 compared to $4.9 million for the fourth quarter of 2019.

Armanino Unveils Vaccine Registration & Administration System to Assist Government Agencies in Vaccine Rollout

Medical specialties, Biotechnology, Vaccination, Life sciences, Vaccine, Medicine, Vaccines, Medical research
Thursday, February 25, 2021 - 7:53pm

The latest addition in our library of solutions, our Vaccine Registration & Administration System is a mobile phone-based application that governmental entities can provide to their citizens to easily schedule their vaccination appointments.

Key Points: 
  • The latest addition in our library of solutions, our Vaccine Registration & Administration System is a mobile phone-based application that governmental entities can provide to their citizens to easily schedule their vaccination appointments.
  • Also, we have introduced our vaccination tracker that shows state-by-state performance on the distribution of vaccines.
  • Agencies register residents on a portal connected to the app, who are then contacted to schedule their first vaccine dose.
  • In addition to its core consulting and accounting practices, Armanino operates its division, AMF Media Group ( www.amfmediagroup.com ), a media and communications services agency.